https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-livesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-lives#u54222Wed, 02 Sep 2026 01:41:17 +0000The FDA has approved daraxonrasib, a daily oral RAS inhibitor, for adults with advanced or metastatic pancreatic cancer. Clinical trials showed the medication nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. The drug blocks a mutated protein to stop tumor growth and was approved more than six months ahead of schedule.Why it mattersPancreatic cancer is a highly aggressive and often fatal disease. The approval of daraxonrasib offers new hope for patients with limited treatment options. The drug's accelerated approval is based on prom https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-lives#u51038Fri, 28 Aug 2026 13:51:53 +0000The FDA granted expedited approval to daraxonrasib, a first-of-a-kind pill for advanced pancreatic cancer. The drug blocks a mutated protein to stop tumor growth in more than 90% of cases. Clinical trials showed the medication nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. The FDA approved the drug more than six months ahead of schedule following these results. Former UF President Ben Sasse credits the medication with extending his life.Why it mattersPancreatic cancer is among the deadliest forms of the disease, historically offering https://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-liveshttps://www.live-feeds.com/feed/fda-approves-landmark-pancreatic-cancer-drug-that-extends-patients-lives#u49880Thu, 27 Aug 2026 10:00:47 +0000The FDA has approved a new pancreatic cancer drug called daraxonrasib, which has shown to extend patients' lives. Studies showed patients taking the pill lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients. This approval marks a significant development in the treatment of pancreatic cancer, a deadly disease. The drug is a first-of-a-kind pill.Why it mattersPancreatic cancer is a highly aggressive and often fatal disease. Current treatment options have limited effectiveness, making the approval of this new drug a significant breakthrough. The FDA's d